- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04176198
Badanie doustnego TP-3654 u pacjentów ze zwłóknieniem szpiku
Faza 1/2, badanie otwarte, zwiększanie dawki, bezpieczeństwo, farmakokinetyka i farmakodynamika doustnego TP-3654 u pacjentów z pierwotnym lub wtórnym zwłóknieniem szpiku średniego lub wysokiego ryzyka
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.
Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.
Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Reyna Bishop
- Numer telefonu: 617-674-6800
- E-mail: reyna.bishop@us.sumitomo-pharma.com
Kopia zapasowa kontaktu do badania
- Nazwa: Jordan Simpson
- E-mail: jordan.simpson@us.sumitomo-pharma.com
Lokalizacje studiów
-
-
-
Adelaide, Australia
- Rekrutacyjny
- Icon Cancer Centre (Ashford Cancer Centre Research)
-
Kontakt:
- Stanley Cheung, MD
- E-mail: Stanley.Cheung@icon.team
-
-
South Australia
-
Adelaide, South Australia, Australia
- Rekrutacyjny
- Royal Adelaide Hospital
-
Kontakt:
- Christine Hoare
- E-mail: christine.hoare@sa.gov.au
-
-
Victoria
-
Box Hill, Victoria, Australia
- Rekrutacyjny
- Eastern Health Box Hill Hospital
-
Kontakt:
- SMPA Investigative Site
-
Clayton, Victoria, Australia
- Rekrutacyjny
- Monash University
-
Kontakt:
- SMPA Investigative Site
-
Fitzroy, Victoria, Australia
- Rekrutacyjny
- St Vincent's Hospital Melbourne
-
Kontakt:
- SMPA Investigative Site
-
Melbourne, Victoria, Australia
- Rekrutacyjny
- Peter McCallum Center
-
Kontakt:
- SMPA Investigative Site
-
Richmond, Victoria, Australia
- Rekrutacyjny
- Epworth Healthcare
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Antwerp, Belgia, 2020
- Rekrutacyjny
- ZNA Cadix
-
Kontakt:
- SMPA Investigative Site
-
Antwerp, Belgia, 2030
- Rekrutacyjny
- ZNA Middelheim
-
Kontakt:
- SMPA Investigative Site
-
Ghent, Belgia, 9000
- Rekrutacyjny
- Universitair Ziekenhuis Gent
-
Kontakt:
- SMPA Investigative Site
-
Liège, Belgia, 4000
- Rekrutacyjny
- CHU de Liege
-
Kontakt:
- SMPA Investigative Site
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgia, 3000
- Rekrutacyjny
- University Hospitals Leuven
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Amiens, Francja, 80054
- Rekrutacyjny
- Centre Hospitalier Universitaire D'Amiens
-
Kontakt:
- SMPA Investigative Site
-
Angers, Francja, 9000
- Rekrutacyjny
- CHU Angers
-
Kontakt:
- SMPA Investigative Site
-
Lyon, Francja, 69495
- Rekrutacyjny
- Centre Hospitalier Lyon Sud
-
Kontakt:
- SMPA Investigative Site
-
Nice, Francja, 06200
- Rekrutacyjny
- Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
-
Kontakt:
- SMPA Investigative Site
-
Nîmes, Francja, 30029
- Rekrutacyjny
- Institut de cancerologie du Gard
-
Kontakt:
- SMPA Investigative Site
-
Nîmes, Francja
- Rekrutacyjny
- Institut de cancerologie du Gard
-
Kontakt:
- SMPA Investigative Site
-
Paris, Francja, 75010
- Rekrutacyjny
- Hospital Saint Louis
-
Kontakt:
- SMPA Investigative Site
-
Poitiers, Francja, 86021
- Rekrutacyjny
- University Hospital of Poitiers
-
Kontakt:
- SMPA Investigative Site
-
Villejuif, Francja, 94805
- Rekrutacyjny
- Institut Gustave Roussy
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Barcelona, Hiszpania
- Rekrutacyjny
- Hospital Universitario y Politecnico La Fe
-
Kontakt:
- SMPA Investigative Site
-
Barcelona, Hiszpania
- Rekrutacyjny
- Institut Catala d'Oncologia
-
Kontakt:
- SMPA Investigative Site
-
Salamanca, Hiszpania
- Rekrutacyjny
- Hospital Universitario de Salamanca
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Aichi, Japonia
- Rekrutacyjny
- Aichi Medical University Hospital
-
Kontakt:
- Akiyoshi Takami
- Numer telefonu: 0561-62-3311
- E-mail: takami.akiyoshi.490@mail.aichi-med-u.ac.jp
-
Aomori, Japonia
- Rekrutacyjny
- Aomori Prefectural Central Hospital
-
Kontakt:
- Tomoaki Akagi, MD
- Numer telefonu: 017-726-8111
- E-mail: tomakagi@med.pref.aomori.jp
-
Chiba, Japonia
- Rekrutacyjny
- National Cancer Center Hospital East
-
Kontakt:
- Junichiro Yuda, MD
- Numer telefonu: 04-7133-1111
- E-mail: jyuda@east.ncc.go.jp
-
Fukuoka, Japonia
- Rekrutacyjny
- Kyushu University Hospital
-
Kontakt:
- Takuji Yamauchi, MD
- Numer telefonu: 092-641-1151
- E-mail: yamauchi.takuji.355@m.kyushu-u.ac.jp
-
Hokkaido, Japonia
- Rekrutacyjny
- Hokkaido University Hospital
-
Kontakt:
- Takanori Teshima, MD
- Numer telefonu: 011-716-1161
- E-mail: teshima@med.hokudai.ac.jp
-
Kamakura, Japonia, 247-8533
- Rekrutacyjny
- Shonan Kamakura General Hospital
-
Kontakt:
- Tomiteru Togano, MD
- Numer telefonu: 0467-46-1717
- E-mail: t_togano@shonankamakura.or.jp
-
Miyazaki, Japonia
- Rekrutacyjny
- University of Miyazaki Hospital
-
Kontakt:
- Kazuya Shimoda, MD
- Numer telefonu: 0985-85-1510
- E-mail: kshimoda@med.miyazaki-u.ac.jp
-
Okayama, Japonia
- Rekrutacyjny
- Okayama University Hospital
-
Kontakt:
- Noboru Asada, MD
- Numer telefonu: 086-223-7151
- E-mail: nasada@okayama-u.ac.jp
-
Osaka, Japonia
- Rekrutacyjny
- The University of Osaka Hospital
-
Kontakt:
- Michiko Ichii, MD
- Numer telefonu: 06-6879-5111
-
Saitama, Japonia
- Zakończony
- Saitama Medical Center
-
Sendai, Japonia
- Rekrutacyjny
- Tohoku University Hospital
-
Kontakt:
- Noriko Fukuhara, MD
- Numer telefonu: 022-717-7000
-
Shizuoka, Japonia
- Zakończony
- Shizuoka Cancer Center
-
Tokyo, Japonia, 160-0023
- Rekrutacyjny
- Tokyo Medical University Hospital
-
Kontakt:
- Daigo Akahane, MD
- Numer telefonu: 03-3342-6111
- E-mail: dakahane@tokyo-med.ac.jp
-
Tokyo, Japonia
- Rekrutacyjny
- Juntendo University Hospital
-
Kontakt:
- Shuichi Shirane, MD
- Numer telefonu: 03-3813-3111
- E-mail: sshirane@juntendo.ac.jp
-
Tokyo, Japonia, 179-0072
- Rekrutacyjny
- Nerima Hikarigaoka Hospital
-
Kontakt:
- Akihiko Gotoh, MD
- Numer telefonu: 03-3979-3611
- E-mail: akgotou@juntendo.ac.jp
-
Tsu, Japonia
- Rekrutacyjny
- Mie University Hospital
-
Kontakt:
- Yuka Sugimoto, MD
- Numer telefonu: 059-232-1111
- E-mail: yuka2@clin.medic.mie-u.ac.jp
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 1N4
- Rekrutacyjny
- University of Calgary
-
Kontakt:
- Sonia Cerquozzi
- E-mail: sonia.cerquozzi@albertahealthservices.ca
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6T 1Z3
- Rekrutacyjny
- University of British Columbia
-
Kontakt:
- SMPA Investigative Site
-
Vancouver, British Columbia, Kanada, V6T 1Z3
- Rekrutacyjny
- St. Paul's Hospital Hematology/Oncology Research
-
Kontakt:
- Kelsi Sorensen
- Numer telefonu: 604-682-2344
- E-mail: ksorensen1@providencehealth.bc
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Rekrutacyjny
- Juravinski Cancer Center
-
Kontakt:
- SMPA Investigative Site
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrutacyjny
- Princess Margaret Cancer Center
-
Kontakt:
- Vikas Gupta
- E-mail: vikas.gupta@uhn.ca
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutacyjny
- Jewish General Hospital
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Halle, Niemcy
- Rekrutacyjny
- Universitätsmedizin Halle
-
Kontakt:
- SMPA Investigative Site
-
Lübeck, Niemcy
- Rekrutacyjny
- Universitätsklinikum Schleswig-Holstein
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35294
- Rekrutacyjny
- University of Alabama
-
Kontakt:
- Tiffany Hill
- Numer telefonu: 205-934-9591
-
-
Arizona
-
Tucson, Arizona, Stany Zjednoczone, 85724
- Rekrutacyjny
- The University of Arizona Cancer Center
-
Kontakt:
- Audrey Johnson
- Numer telefonu: 520-694-9084
- E-mail: audieejayy@arizona.edu
-
-
California
-
Duarte, California, Stany Zjednoczone, 91010
- Rekrutacyjny
- City of Hope
-
Kontakt:
- Michelle Velasquez
- Numer telefonu: 626-218-3524
- E-mail: mvelaszuez@coh.org
-
Los Angeles, California, Stany Zjednoczone, 90033
- Rekrutacyjny
- University of Southern California
-
Kontakt:
- Shirley Sian
- Numer telefonu: 323-865-0456
- E-mail: sian_s@med.usc.edu
-
Newport Beach, California, Stany Zjednoczone, 92663
- Rekrutacyjny
- Hoag Family Cancer Institute
-
Kontakt:
- Patrice Jones
- Numer telefonu: 949-764-5501
- E-mail: patrice.jones@hoag.org
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80218
- Rekrutacyjny
- Blood Cancer Center
-
Kontakt:
- Brooke Rhodes
- E-mail: Brookerhodes@sarahcannon.com
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06510
- Rekrutacyjny
- Yale School of Medicine
-
Kontakt:
- Farah Fasihuddin
- Numer telefonu: 203-494-4610
- E-mail: farah.fasihuddin@yale.edu
-
-
Florida
-
Gainesville, Florida, Stany Zjednoczone, 32608
- Zakończony
- University of Florida Health Shands Cancer Hospital
-
Miami, Florida, Stany Zjednoczone, 33136
- Rekrutacyjny
- University of Miami
-
Kontakt:
- Alessia Zoso
- Numer telefonu: 305-243-0327
- E-mail: azoso@miami.edu
-
Miami, Florida, Stany Zjednoczone, 33176
- Rekrutacyjny
- Baptist Health - Miami Cancer Institute
-
Kontakt:
- Firas El Chaer, MD
- Numer telefonu: 786-596-2000
- E-mail: firas.elchaer@baptisthealth.net
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Rekrutacyjny
- Emory University
-
Kontakt:
- Suzanne Scott
- Numer telefonu: 404-778-4334
- E-mail: suzanne.e.scott@emory.edu
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Rekrutacyjny
- University of Chicago
-
Kontakt:
- Howie Weiner
- E-mail: HWeiner@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21201
- Rekrutacyjny
- University of Maryland
-
Kontakt:
- Maria Baer, MD
- Numer telefonu: 410-328-8708
- E-mail: mbaer@umm.edu
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Rekrutacyjny
- Massachusetts General Hospital
-
Kontakt:
- Gabriela Hobbs, MD
- E-mail: ghobbs@mgb.org
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- Rekrutacyjny
- University of Michigan
-
Kontakt:
- Kelsey Bolin
- Numer telefonu: 734-936-2193
- E-mail: kntillma@med.umich.edu
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55455
- Rekrutacyjny
- University of Minnesota
-
Kontakt:
- Naveen Premnath, MD
- E-mail: premn007@umn.edu
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Rekrutacyjny
- Washington University of Medicine
-
Kontakt:
- Nicole Gaudin
- Numer telefonu: 314-747-7960
- E-mail: nrgaudin@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Rekrutacyjny
- John Theurer Cancer Center at Hackensack University Medical Center
-
Kontakt:
- Parita Patel
- Numer telefonu: 551-996-5900
- E-mail: parita.patel@hmhn.org
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14263
- Zakończony
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Stany Zjednoczone, 10065
- Rekrutacyjny
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Tamanna Haque, MD
- E-mail: haquet1@mskcc.org
-
New York, New York, Stany Zjednoczone, 10029
- Rekrutacyjny
- Icahn School of Medicine at Mount Sinai
-
Kontakt:
- Gabriela Bello
- E-mail: gabriela.bello@mssm.edu
-
New York, New York, Stany Zjednoczone, 10065
- Rekrutacyjny
- Weill Cornell Medical Center
-
Kontakt:
- Penina Steward
- Numer telefonu: 212-746-1858
- E-mail: pes4006@med.cornell.edu
-
The Bronx, New York, Stany Zjednoczone, 10461
- Rekrutacyjny
- Montefiore Cancer Center
-
Kontakt:
- Olivia Orellano
- E-mail: oorellano@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Rekrutacyjny
- Duke Cancer Institute
-
Kontakt:
- Ben Dosan
- E-mail: benjamin.dosan@duke.edu
-
-
Ohio
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Rekrutacyjny
- Ohio State University
-
Kontakt:
- Molly Brandenburg
- Numer telefonu: 614-366-7951
- E-mail: Molly.Brandenburg@osumc.edu
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Rekrutacyjny
- Medical University of South Carolina
-
Kontakt:
- Jared Hortman
- E-mail: hortman@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Rekrutacyjny
- Vanderbilt University
-
Kontakt:
- SMPA Investigative Site
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- Rekrutacyjny
- Tri-Star Centennial Medical Center
-
Kontakt:
- Brooke Rhodes
- E-mail: brooke.rhodes@sarahcannon.com
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77054
- Rekrutacyjny
- MD Anderson Cancer Center
-
Kontakt:
- Kurt Schroeder
- Numer telefonu: 713-745-2232
- E-mail: kdschroe@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Rekrutacyjny
- Huntsman Cancer Institute
-
Kontakt:
- Nicole Fisher
- Numer telefonu: 801-587-7000
- E-mail: nicole.fisher@hci.utah.edu
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22903
- Rekrutacyjny
- University of Virginia Cancer Center
-
Kontakt:
- Avani Hopkins
- Numer telefonu: 434-243-8108
- E-mail: AJH7JQE@uvahealth.org
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98109
- Rekrutacyjny
- University of Washington - Fred Hutchinson Cancer Center
-
Kontakt:
- Anna Halpern
- E-mail: halpern2@uw.edu
-
-
-
-
-
Alessandria, Włochy, 15121
- Rekrutacyjny
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
-
Kontakt:
- SMPA Investigative Site
-
Aviano, Włochy, 33081
- Rekrutacyjny
- Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
-
Bologna, Włochy, 40138
- Rekrutacyjny
- IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
-
Kontakt:
- SMPA Investigative Site
-
Brescia, Włochy
- Rekrutacyjny
- ASST - Spedali Civili di Brescia
-
Kontakt:
- SMPA Investigative Site
-
Meldola, Włochy, 47014
- Rekrutacyjny
- IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
-
Kontakt:
- SMPA Investigative Site
-
Milan, Włochy, 20122
- Rekrutacyjny
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Kontakt:
- SMPA Investigative Site
-
Torino, Włochy, 10126
- Rekrutacyjny
- Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
-
Kontakt:
- SMPA Investigative Site
-
-
-
-
-
Lincoln, Zjednoczone Królestwo
- Rekrutacyjny
- Lincoln County Hospital
-
Kontakt:
- SMPA Investigative Site
-
Lincoln, Zjednoczone Królestwo
- Rekrutacyjny
- United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
-
Kontakt:
- SMPA Investigative Site
-
London, Zjednoczone Królestwo
- Rekrutacyjny
- University College London Hospital's NHS foundation Trust
-
Kontakt:
- SMPA Investigative Site
-
Oxford, Zjednoczone Królestwo
- Rekrutacyjny
- Oxford University Hospitals NHS Foundation
-
Kontakt:
- SMPA Investigative Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Patients must meet all of the following inclusion criteria to be eligible:
Nuvisertib (TP-3654) Monotherapy Arm:
- Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
- Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
- Fulfill the following clinical laboratory parameters:
- Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
- ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5%
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
- Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
- Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
- On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
- Fulfills the following clinical laboratory parameters:
- Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Nuvisertib (TP-3654) + Momelotinib Arm
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
- Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
- Fulfills the following clinical laboratory parameters:
- Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
- Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:
Nuvisertib (TP-3654) Monotherapy Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy.
- Prior allogeneic stem cell transplant within the last 6 months.
- Eligible for allogeneic bone marrow or stem cell transplantation.
- Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
- History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
- Corrected QT interval > 480msec.
- Prior or concurrent malignancy that could interfere with the investigational regime.
- Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
- Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
- Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
- Pregnant or breastfeeding
- Currently receiving any other investigational agent.
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
- Known allergic reactions or sensitivity to nuvisertib, or similar compound.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy
- Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Nuvisertib (TP-3654) + Momelotinib Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
- Splenic irradiation within 6 months prior to screening or prior splenectomy
- Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- Presence of Grade ≥ 2 peripheral neuropathy
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Ramię 1: nuvisertib (TP-3654)
|
Oral PIM Inhibitor
Inne nazwy:
|
|
Eksperymentalny: Ramię 2: nuvisertib (TP-3654) dodany do ruksolitynibu
|
Oral PIM Inhibitor
Inne nazwy:
Oral JAK inhibitor
Inne nazwy:
|
|
Eksperymentalny: Ramię 3: nuvisertib (TP-3654) w skojarzeniu z momelotynibem
|
Oral PIM Inhibitor
Inne nazwy:
Oral JAK inhibitor
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Determine the incidence of dose-limiting toxicities (DLTs)
Ramy czasowe: 28 days
|
Number of participants with DLTs |
28 days
|
|
Determine the incidence of treatment emergent adverse events
Ramy czasowe: From start of treatment to end of study
|
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events |
From start of treatment to end of study
|
|
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
Ramy czasowe: From start of treatment to end of study
|
Number of participants with ≥ 35% spleen volume reduction (SVR35) |
From start of treatment to end of study
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of participants achieving objective response by IWG-MRT response criteria
Ramy czasowe: From start of treatment to end of study
|
Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease. |
From start of treatment to end of study
|
|
Number of participants who have ≥ 25% spleen volume reduction
Ramy czasowe: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
Number of participants who have ≥ 25% spleen volume reduction compared to baseline |
Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
|
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
Ramy czasowe: 24 weeks
|
Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment. |
24 weeks
|
|
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
Ramy czasowe: After 24 weeks of treatment to end of study
|
Change in PGIC score |
After 24 weeks of treatment to end of study
|
|
Determine the incidence of QT interval changes
Ramy czasowe: 25 hours
|
Changes in QT interval and heart rhythm |
25 hours
|
|
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Ramy czasowe: 24 hours
|
The estimate of time for the nuvisertib concentration or amount to be reduced by half |
24 hours
|
|
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Ramy czasowe: 24 hours
|
The amount of drug exposure over 24 hours period after administration |
24 hours
|
|
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Ramy czasowe: 24 hours
|
The maximum nuvisertib concentration after administration |
24 hours
|
|
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
Ramy czasowe: 24 hours
|
The time to reach maximum nuvisertib concentration |
24 hours
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Liczba pacjentów, u których doszło do zmniejszenia zwłóknienia szpiku kostnego
Ramy czasowe: Co 24 tygodnie do końca badania
|
Co 24 tygodnie do końca badania
|
|
|
Ramiona leczenia skojarzonego nuvisertibem: ocena wzrostu stężenia hemoglobiny ≥1,5 lub ≥ 2 g/dl w stosunku do wartości wyjściowych
Ramy czasowe: Od rozpoczęcia leczenia do zakończenia badania
|
Od rozpoczęcia leczenia do zakończenia badania
|
|
|
Ramiona leczenia skojarzonego nuvisertibem: ocena statusu niezależności od transfuzji krwinek czerwonych lub wszelkich zmian w wymaganiach
Ramy czasowe: Od rozpoczęcia leczenia do zakończenia badania
|
Od rozpoczęcia leczenia do zakończenia badania
|
|
|
Nuvisertib Monoterapia: zmiany liczby płytek krwi w czasie u pacjentów z wyjściową liczbą płytek krwi <100 x 10^9/l
Ramy czasowe: Od początku leczenia do końca badania
|
Od początku leczenia do końca badania
|
|
|
Study potential pharmacodynamic (PD) markers of nuvisertib
Ramy czasowe: 12 months
|
Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples. |
12 months
|
|
Establish overall survival
Ramy czasowe: From start of treatment to end of study
|
The time interval from treatment start date to date of death from any cause |
From start of treatment to end of study
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- BBI-TP-3654-102
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .